The runaway immune response to infection called sepsis is difficult to diagnose, and even more difficult to treat. Now, researchers have discovered a biomarker called methylthioadenosine (MTA) that can predict which patients are most likely to die from the disease. The findings could also help determine whether patients could benefit from therapies that either enhance or suppress the immune system, paving the way for new treatments.